Literature DB >> 12019280

Resistant hypertension: comparing hemodynamic management to specialist care.

Sandra J Taler1, Stephen C Textor, Jo Ellen Augustine.   

Abstract

Although resistant hypertension affects a minority of all hypertensives, this group continues to experience disproportionately high cardiovascular event rates despite newer antihypertensive agents. Hypertension represents an imbalance of hemodynamic forces within the circulation, usually characterized by elevated systemic vascular resistance. We studied the utility of serial hemodynamic parameters in the selection and titration of antihypertensive medication in resistant hypertensive patients using highly reproducible noninvasive measurements by thoracic bioimpedance. Resistant hypertension patients (n=104) were randomized to drug selection based either on serial hemodynamic (HD) measurements and a predefined algorithm or on drug selection directed by a hypertension specialist (SC) in a 3-month intensive treatment program. Blood pressure was lowered by intensified drug therapy in both treatment groups (169+/-3/87+/-2 to 139+/-2/72+/-1 mm Hg HD versus 173+/-3/91+/-2 to 147+/-2/79+/-1 mm Hg SC, P<0.01 for systolic and diastolic BP), using similar numbers and intensity of antihypertensive medications. Blood pressures were reduced further for those treated according to hemodynamic measurements, resulting in improved control rates (56% HD versus 33% SC controlled to </=140/90 mm Hg, P<0.05) and incremental reduction in systemic vascular resistance measurements. Although the number of patients taking diuretics did not differ between groups, final diuretic dosage was higher in the hemodynamic cohort. Our results demonstrate superior blood pressure control using a treatment algorithm and serial hemodynamic measurements compared with clinical judgment alone in a randomized prospective study. Our measurements of thoracic fluid volume support occult volume expansion as a mediator of antihypertensive drug resistance and use of impedance measurements to guide advancing diuretic dose and adjustment of multidrug antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019280     DOI: 10.1161/01.hyp.0000016176.16042.2f

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  85 in total

1.  Who benefits more from hemodynamically guided hypotensive therapy? The experience from two randomized, prospective and controlled trials.

Authors:  Paweł Krzesiński; Grzegorz Gielerak; Adam Stańczyk; Katarzyna Piotrowicz; Andrzej Skrobowski
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-12-02

Review 2.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

3.  [Resistant hypertension : What is it?].

Authors:  F C Luft
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

4.  Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study.

Authors:  Leyla Cekici; Arschang Valipour; Robab Kohansal; Otto Chris Burghuber
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

Review 5.  Should chlorthalidone be the diuretic of choice for antihypertensive therapy?

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

6.  An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade.

Authors:  Scott Martin Vouri; Joseph S van Tuyl; Margaret A Olsen; Hong Xian; Mario Schootman
Journal:  J Am Pharm Assoc (2003)       Date:  2018-07-20

Review 7.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

8.  Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis.

Authors:  Panagiota Anyfanti; Eugenia Gkaliagkousi; Eleni Gavriilaki; Areti Triantafyllou; Panagiotis Dolgyras; Vasiliki Galanopoulou; Spyros Aslanidis; Stella Douma
Journal:  Clin Cardiol       Date:  2018-11-27       Impact factor: 2.882

Review 9.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 10.  Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.